Summary
This 2009 narrative review synthesises epidemiological and mechanistic evidence linking omega-3 polyunsaturated fatty acids—particularly docosahexaenoic acid (DHA)—to reduced risk of age-related cognitive decline and Alzheimer's disease. The authors describe multiple neuroprotective pathways for DHA, including suppression of amyloid-β accumulation and tau phosphorylation, whilst noting that protective effects may be limited by ApoE4 genotype in some individuals. The review concludes that clinical trials of omega-3 supplementation are warranted, particularly when initiated early or combined with antioxidants.
Regional applicability
The epidemiological findings and mechanistic insights are globally relevant and applicable to United Kingdom dementia prevention strategies. However, the review does not address UK-specific dietary patterns, food supply sources of omega-3, or health system implementation; direct translation to UK clinical practice would require localisation studies and health economic evaluation.
Key measures
Dietary omega-3 intake, blood DHA levels, cognitive decline, dementia diagnosis, amyloid-β production, tau phosphorylation, neurofibrillary tangle pathology
Outcomes reported
The review synthesised epidemiological evidence linking omega-3 fatty acid intake and blood levels to dementia and cognitive decline risk, and examined biological mechanisms by which docosahexaenoic acid (DHA) may confer neuroprotection.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.